1、《关于部分募投项目延期的议案》 根据募集资金实际使用以及募投项目实施情况，为保证募投项目建设更符合 公司和股东利益，公司拟将首次公开发行股票募投项目中的"总部生产基地建设 项目"预计达到可使用状态时间由 2024 年 7 月调整为 2025 年 12 月。本次募投项 目延期事项不改变募集资金的用途，不会对公司正常的生产经营和业务发展产生 不利影响。根据《上海证券交易所股票上市规则》《威海百合生物技术股份有限 公司章程》等相关规定，本事项无需提交股东大会审议。 证券代码：603102 证券简称：百合股份 公告编号：2024-018 威海百合生物技术股份有限公司 第四届董事会第八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 威海百合生物技术股份有限公司（以下简称"公司"）于 2024 年 7 月 12 日向 各位董事发出了召开第四届董事会第八次会议的通知。2024 年 7 月 18 日，第四 届董事会第八次会议以通讯及现场投票相结合的表决方式在公司会议室召开，应 出席本次会议的董事 9 ...

证券代码：603102 证券简称：百合股份 公告编号：2024-017 威海百合生物技术股份有限公司（以下简称"公司"）已于 2024 年 4 月 12 日发布公司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年 度经营成果、财务状况，公司计划于 2024 年 6 月 5 日下午 15:00-16:00 举行 2023 年度业绩说明会，就投资者关心的问题进行交流。 威海百合生物技术股份有限公司 关于召开 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任 。 重要内容提示： 投资者可于 2024 年 6 月 4 日（星期二）16:00 前通过公司邮箱 suntongbo@sohu.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 ...

证券代码：603102 证券简称：百合股份 公告编号：2024-016 威海百合生物技术股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.75 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/5/31 | － | 2024/6/3 | 2024/6/3 | 差异化分红送转： 是 1. 发放年度：2023 年年度 2. 分派对象： 3. 差异化分红送转方案： （1）差异化分红方案 公司通过回购专用证券账户所持有本公司股份不参与本次利润分配。如公司在《2023 年 度利润分配方案公告》披露之日起至实施权益分派股权登记日期间，因可转债转股/回购股份/ 股权激励授予股份回购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公司 拟维持每股分配比例不变，相应调整分配总额。 （2）本次差异化分 ...

公司于 2024 年 3 月 26 日披露《威海百合生物技术股份有限公司关于公司股 份回购实施结果公告》，公司于 2024 年 3 月 23 日完成回购，已实际回购公司股 份 1,020,400 股，占公司总股本的 1.59%。 广发证券股份有限公司 关于威海百合生物技术股份有限公司差异化权益分派事项 的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐人"）作为威海百 合生物技术股份有限公司（以下简称"百合股份"、"上市公司"或"公司"）首 次公开发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股 份》《上海证券交易所上市公司自律监管指南第 2 号—业务办理》等相关法律法 规的要求，对百合股份差异化权益分派事项进行了审慎核查，具体情况如下： 一、本次差异化权益分派的原因 公司于 2023 年 3 月 24 日召开第四届董事会第三次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，并于 2023 年 3 月 31 日披露了 《关于以集中竞价交易方式回购公司股份的回购报告书》，拟回购公司股份资金 ...

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 威海百合生物技术股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603102 证券简称：百合股份 公告编号：2024-015 | 1、出席会议的股东和代理人人数 | 42 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 37,261,486 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 59.16 | 注：截至本次股东大会股权登记日，公司回购专用账户中共有公司股份 1,020,400 股，根据 《上市公司股份回购规则》等相关规定，该部分股份不享有股东大会表决权，本次股东大会 计算相关比例时已扣除上述已回购股份。 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 (一) 股东大会召开的时间：2024 年 5 月 8 日 (二) 股东大会召开的地点：山东省威海市荣成市荣义路 2899 号公司 ...

Elin = APT Law Offices 关于威海百合生物技术股份有限公司 2023 年年度股东大会的法律意见 致:威海百合生物技术股份有限公司 威海百合生物技术股份有限公司(以下简称"公司")2023年年度股东大 会(以下简称"本次股东大会")于 2024年5月8日召开,北京市君泽君律师 事务所(以下简称"本所")接受公司的委托,就公司本次股东大会的相关事宜 出具法律意见。 本所及经办律师依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》《律师事务所从事证券法律业务管理办法》和《律师 事务所证券法律业务执业规则(试行)》等规定及本法律意见出具日以前已经发 生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进 行了充分的核查验证,保证本法律意见所认定的事实真实、准确、完整,所发表 的结论性意见合法、准确,不存在虚假记载、误导性陈述或者重大遗漏,并承担 相应法律责任。 为出具本法律意见,本所律师出席本次股东大会,审查关于本次股东大会的 公告、出席股东大会的股东资格、本次股东大会决议和记录,并参与本次股东大 会的监票工作。 北京市东城区金宝街 89 号金宝大厦 1 ...

Group 1: Financial Performance - In Q1 2024, the company's revenue and profit experienced a decline compared to the previous year due to special events impacting market demand [1] - The sales gross margin for Q1 2024 was reported at 40.15%, with plans to maintain a high gross margin in the future [2] Group 2: Business Strategy - The company aims for double-digit growth in 2024, focusing on large customer strategies and increasing participation in industry exhibitions and forums [1] - The company plans to enhance its own brand promotion, particularly for its brand "Baihe Kang" [1] Group 3: Market Demand and Customer Base - The current business growth relies on major domestic single-product customers and numerous high-growth clients, with a strong ability to customize and deliver personalized products [2] - The company intends to increase the revenue share from its own brand business while maintaining a stable development of contract manufacturing [2] Group 4: Future Plans and Industry Trends - A stock incentive plan is expected to be introduced to cover core management and key personnel, aiming for maximum motivational effect [2] - The company is exploring the competitive landscape, considering whether industry concentration will shift towards brand or OEM sides, with new entrants likely favoring a light asset model [2][3]

Financial Performance - The company's operating revenue for Q1 2024 was ¥188,638,808.65, representing a decrease of 18.68% compared to the same period last year[4]. - The net profit attributable to shareholders was ¥34,850,457.04, down 22.18% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥34,730,392.94, a decrease of 20.46% compared to the previous year[4]. - Total revenue for Q1 2024 was ¥188,638,808.65, a decrease of 18.6% compared to ¥231,965,285.09 in Q1 2023[17]. - Net profit for Q1 2024 was ¥34,850,457.04, a decline of 22.2% from ¥44,783,221.82 in Q1 2023[18]. - Operating profit for Q1 2024 was ¥39,864,164.04, down 22.5% from ¥51,434,864.07 in Q1 2023[18]. - The basic earnings per share were ¥0.54, reflecting a decrease of 22.86% year-on-year[4]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.54, down from ¥0.70 in Q1 2023, reflecting a decline of 22.9%[19]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 160.91%, amounting to ¥26,771,614.42, primarily due to a reduction in material payments[4][7]. - Cash inflow from operating activities for Q1 2024 was ¥186,142,054.34, a decrease of 17.7% from ¥226,025,236.83 in Q1 2023[22]. - The net cash flow from operating activities increased to ¥26,771,614.42 in Q1 2024, compared to ¥10,261,019.33 in Q1 2023, marking a significant improvement[22]. - The company's cash and cash equivalents at the end of Q1 2024 were ¥1,090,598,121.97, down from ¥1,135,618,048.31 at the beginning of the quarter[23]. - The total cash outflow from investing activities in Q1 2024 was ¥74,733,254.38, compared to ¥67,899,071.89 in Q1 2023, indicating increased investment activity[23]. - The company reported a net cash outflow from financing activities of ¥641,077.83 in Q1 2024, reflecting cash used for financing purposes[23]. - The company reported a net cash decrease of ¥45.12 million in Q1 2024, an improvement from a decrease of ¥56.16 million in Q1 2023[34]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,741,776,175.48, a slight increase of 0.32% from the end of the previous year[4]. - The company's total assets increased to ¥1,741,776,175.48 in Q1 2024 from ¥1,736,159,386.58 in Q1 2023, reflecting a growth of 0.1%[14]. - Total liabilities decreased to ¥193,067,939.64 in Q1 2024 from ¥221,695,214.78 in Q1 2023, a reduction of 12.9%[15]. - The total liabilities decreased to ¥189.93 million in Q1 2024 from ¥221.66 million in Q1 2023, a reduction of approximately 14.4%[27]. - The total equity increased to ¥1,596.32 million in Q1 2024, up from ¥1,559.47 million in Q1 2023, reflecting a growth of 2.4%[27]. - The company's total assets amounted to ¥1,786.26 million in Q1 2024, slightly up from ¥1,781.13 million in Q1 2023[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,091[9]. - The equity attributable to shareholders increased by 2.26% to ¥1,548,708,235.84 compared to the end of the previous year[4]. Research and Development - Research and development expenses for Q1 2024 were ¥7,382,842.54, an increase of 9.1% compared to ¥6,765,422.11 in Q1 2023[18]. - Research and development expenses rose to ¥7.38 million in Q1 2024, compared to ¥6.77 million in Q1 2023, indicating a 9.0% increase[29]. Strategic Focus - The company aims to enhance its market presence and is focusing on new product development and technology advancements[16].

Dividend Distribution - The company plans to distribute a cash dividend of 7.50 RMB per 10 shares, totaling approximately 47,234,700 RMB (including tax) based on the total share capital of 62,979,600 shares after repurchase adjustments[6]. - The total cash dividend for 2023, including share repurchase amounts, is 85,471,828.76 RMB (including tax), representing 50.56% of the net profit attributable to shareholders[7]. - The profit distribution proposal is subject to approval at the company's shareholder meeting[8]. - The company has established a cash dividend policy that mandates a minimum of 10% of the distributable profit to be distributed as cash dividends when conditions are met[144]. - The total dividend amount, including cash buybacks, reached 85,471,828.76 RMB, representing 50.56% of the net profit attributable to ordinary shareholders in the consolidated financial statements[148]. Financial Performance - In 2023, the company's operating revenue reached approximately RMB 871.25 million, representing a year-on-year increase of 20.12% compared to RMB 725.33 million in 2022[27]. - The net profit attributable to shareholders was approximately RMB 169.07 million, an increase of 22.65% from RMB 137.84 million in 2022[27]. - The basic earnings per share rose to RMB 2.64, reflecting a growth of 20.00% compared to RMB 2.20 in the previous year[27]. - The net cash flow from operating activities increased by 26.78% to RMB 193.85 million, up from RMB 152.91 million in 2022[27]. - The total assets of the company at the end of 2023 were approximately RMB 1.74 billion, a 4.46% increase from RMB 1.66 billion at the end of 2022[27]. Research and Development - The company's R&D investment in 2023 was ¥30,948,500, accounting for 3.55% of total revenue, which is a 37.51% increase compared to the previous year[37]. - The company obtained 147 health food registration certificates and 4 authorized invention patents in 2023, enhancing its competitive advantage in R&D[37]. - The total number of R&D personnel is 150, making up 13.39% of the total workforce[84]. Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[27]. - The company is focusing on developing new product lines, including infant supplementary foods and sports nutrition products, to strengthen its market position[63]. - The company plans to implement a "big single product strategy" in 2024, focusing on affordable and high-volume sales through deep cooperation with key offline pharmacies[108]. - The company aims to expand its self-owned brand channel layout and explore more precise private domain e-commerce operations in 2024[39]. Compliance and Governance - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has maintained a clear and transparent cash dividend policy, ensuring that minority shareholders have opportunities to express their opinions[146]. Operational Efficiency - The company is focused on enhancing its operational efficiency and exploring potential mergers and acquisitions to strengthen its market position[27]. - The company has implemented a quality control system certified by 12 different international standards, ensuring product safety and reliability[61]. - The company has established a robust talent development strategy, focusing on enhancing the capabilities of its marketing team, particularly for its own brand sales team, through regular training and a learning organization[41]. Risk Management - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors, highlighting investment risks[10]. - The company has not disclosed any significant risks that could affect the authenticity, accuracy, and completeness of the annual report[11]. - The company faces risks related to technology leakage and core talent loss, which could impact its competitive edge and business development[112]. Corporate Social Responsibility - Total donations for public welfare projects amounted to 520,000 CNY, specifically for the 2023 Charity Day event[156]. - The company has not disclosed a separate social responsibility or ESG report[157]. - There are no measures reported for carbon emission reduction during the reporting period[158]. Shareholder Commitments - The controlling shareholder has pledged to avoid any business activities that may compete with the company's operations, ensuring that any related income will belong to the company[167]. - The company will disclose any related transactions in accordance with regulatory requirements and will not use such transactions to transfer profits[169]. - The company has committed to measures to ensure the fulfillment of diluted immediate return commitments by its directors and senior management[174].

一、独立董事的基本情况 本人作为公司独立董事，属于行业内专业人士，任职上市公司独立董事家数 不超过 3 家。 本人在董事会专门委员会的任职情况如下：提名委员会主任委员、薪酬与考 核委员会委员。 威海百合生物技术股份有限公司 2023 年度独立董事述职度报告（李秉胜） 各位股东及股东代表： 作为威海百合生物技术股份有限公司（以下简称"公司"）的独立董事，我 在职期间严格按照《公司法》《上市公司治理准则》《上市公司独立董事管理办 法》等法律法规和公司《公司章程》《独立董事工作细则》等的规定和要求，忠 实、勤勉履职，积极出席相关会议，认真审议各项议案，对公司重大事项发表相 关意见，有效维护公司及全体股东尤其是中小股东的合法权益。现就 2023 年度 （以下简称"报告期内"）履职情况报告如下： （一）个人工作履历、专业背景及任职情况 1962 年出生，中国国籍，无永久境外居留权，博士研究生学历，曾任济南 军区总医院医师、主任医师，现任解放军 960 医院主任医师，现任公司独立董事。 （二）独立性的情况说明 作为公司独立董事，我符合《上市公司独立董事管理办法》第六条规定的独 立性要求，不存在影响独立性的情况。 二、独立 ...